Insights into ASX Stocks
Fortescue (ASX: FMG) Share Price Is Climbing Again as Iron Ore Momentum Returns to the ASX
Fortescue (ASX: FMG) shares have rebounded on stronger iron ore prices, improving Chinese demand and solid shipments. Sentiment is also lifted by dividends and production strength, while its green energy transition and decarbonisation plans support long-term growth above A$20 momentum.
Can Develop Global (ASX: DVP) Sustain Its Breakout Toward New Highs?
Develop Global (ASX: DVP) is gaining momentum as Woodlawn reaches steady-state production, Sulphur Springs economics improve, and mining services expand. Supported by strong copper and zinc markets, the company’s breakout reflects operational execution, contract growth, and multiple upcoming catalysts.
Is Arafura Rare Earths (ASX: ARU) Ready to Make Its Next Move Higher?
Arafura Rare Earths is advancing its Nolans project as a major non-China NdPr supplier, supported by strategic offtakes, sector tailwinds, and improving technical momentum, though investors still face key risks including funding, execution delays, and rare earth price volatility.
Elevra Lithium (ASX: ELV) Share Price Just Hit Fresh Highs Amid Lithium Momentum
Elevra Lithium has surged over 400% amid stronger lithium prices, record revenue, and growing EV demand. Backed by North America’s largest hard-rock lithium mine, ELV remains technically bullish, with investors closely watching a breakout above A$14.20.
Is Dateline Resources (ASX: DTR) Positioning for Stabilisation After Extended Weakness?
Dateline Resources (ASX: DTR) is advancing its California-based gold and rare earth projects while navigating funding, dilution, and execution risks. Technically, the stock is testing major long-term support near 0.16, with RSI conditions suggesting a possible stabilisation phase if buying interest returns.
CSL (ASX: CSL) Shares Sink After Massive Impairment Shock Hits Market Confidence
CSL shares crashed after a US$5 billion impairment warning and weaker guidance shocked investors, sending the stock below A$100. Despite strong long-term fundamentals in plasma therapies, technical indicators remain bearish with heavy selling pressure still dominating the chart.